Blood Cancer Groups Unite to Award $6.75M to ‘Propel Discoveries’

Blood Cancer Groups Unite to Award $6.75M to ‘Propel Discoveries’

A program created by three advocacy groups has awarded more than $6.75 million in multiyear grants to nine scientists whose work might drive a new generation of blood cancer treatments.

The Blood Cancer Discoveries Grant Program (BCDG) is supported by the Leukemia & Lymphoma Society (LLS), the Mark Foundation for Cancer Research, and the Paul G. Allen Frontiers Group.

This new program’s goal is to encourage established blood cancer investigators to conduct critical basic research in hopes of finding novel ways to treat disorders including leukemia, lymphomamyeloma, and myelodysplastic syndromes (MDS). Combined, these cancers are the second-leading cause of death in the U.S.

Through these grants, scientists also hope to better understand blood cancer disease mechanisms — including those involving acute myeloid leukemia (AML) — and help develop better ways of detecting and monitoring disease progression.

“Over our 70-year history, the Leukemia & Lymphoma Society has been at the forefront of revolutionary cancer treatments, from the early days of chemotherapy and stem cell transplantation to the leading edge discoveries of immunotherapy and precision medicine, our investment in research is nearly $1.3 billion over that time,” Lee Greenberger, LLS chief scientific officer, said in a press release.

“With this new initiative, LLS maintains its role as a driver of innovation, supporting early-stage research to propel discoveries that might lead to the next generation of treatments and cures, and help accelerate promising therapies to patients.”

The BCDG supports foundational research that could lead to advances in the treatment and cure of blood cancers. Each project is supported by a three-year $750,000 award. Visit this site for more information.

“This three-way partnership among foundations will accelerate our understanding of cancer biology by empowering some of the brightest scientists to simultaneously probe unique but challenging areas of unmet need,” said Michele Clearly, PhD, CEO of the Mark Foundation. “We look forward to the discoveries that will result from these efforts.”

Grant recipients are:

More information on each recipient is available here. Each of their projects will be supported by a $750,000 grant given over three years.

“Our organization is committed to pushing the boundaries of bioscience and accelerating discoveries to make a difference for humankind,” said Kathryn Richmond, Ph.D., MBA, director of the Frontiers Group, “and we believe these grants will be a catalyst that will spark innovative new directions in blood cancer research.”